Sorafenib for RCC Well-Tolerated in Older Patients

Results from a retrospective analysis indicate that the use of the antiangiogenic, VEGF inhibitor sorafenib for the treatment of advanced renal cell carcinoma was well tolerated in patients aged 65 years or older.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news